Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5¬HT) transporter inhibitor as well as 5¬HT3A and 5¬HT7 receptors antagonist, 5¬HT1A and 5¬HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD).
Current and future perspectives on the Major Depressive Disorder: Focus on the new multimodal antidepressant Vortioxetine / Orsolini, Laura; Tomasetti, Carmine; Valchera, Alessandro; Iasevoli, Felice; Buonaguro, ELISABETTA FILOMENA; Fornaro, Michele; Fiengo, ANNASTASIA LUCIA CARMELA; Martinotti, Giovanni; Vellante, Federica; Matarazzo, Ilaria; Vecchiotti, Roberta; Perna, Giampaolo; Di Nicola, Marco; Carano, Alessandro; DE BARTOLOMEIS, Andrea; Di Giannantonio, Massimo; De Berardis, Domenico. - In: CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS. - ISSN 1871-5273. - Epub ahead of print:(2016). [10.2174/1871527315666161025140111]
Current and future perspectives on the Major Depressive Disorder: Focus on the new multimodal antidepressant Vortioxetine
TOMASETTI, CARMINE;IASEVOLI, FELICE;BUONAGURO, ELISABETTA FILOMENA;Fornaro, Michele;FIENGO, ANNASTASIA LUCIA CARMELA;DE BARTOLOMEIS, ANDREA;
2016
Abstract
Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5¬HT) transporter inhibitor as well as 5¬HT3A and 5¬HT7 receptors antagonist, 5¬HT1A and 5¬HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD).| File | Dimensione | Formato | |
|---|---|---|---|
|
In-press (final).pdf
non disponibili
Tipologia:
Documento in Pre-print
Licenza:
Accesso privato/ristretto
Dimensione
771.39 kB
Formato
Adobe PDF
|
771.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
